Find a Study

STUDY SEARCH RESULTS
  Notify Me When Search is Updated

15 studies found for your search request:  Mk2870

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients with Bladder Cancer (MK-2870-027)
Condition: Non-Muscle Invasive Bladder Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06637423
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study of Sacituzumab tirumotecan (MK-2870) as a Single Agent and in Combination with Pembrolizumab...
Condition: Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06312176
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as Monotherapy and in Combination with Pembrol...
Condition: Triple Negative Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06841354
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab tirumotecan (MK- ...
Condition: Non small cell lung cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06312137
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination with Pembrolizumab (MK-3475) Ver...
Condition: Endometrial cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: Female
Study ID: NCT06952504
Status: Recruiting
Has Enrolling Locations in US or Canada



Copyright © 2025 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site

Accessibility icon